Business Description
Guizhou Sanli Pharmaceutical Co Ltd
ISIN : CNE1000040B4
Share Class Description:
SHSE:603439: Class ATotal Employee Number:
1,887Compare
Compare
Traded in other countries / regions
603439.China Index Membership
SSE Composite Index IPO Date
2020-04-28Description
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.53 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.47 | |||||
Debt-to-EBITDA | 8.43 | |||||
Interest Coverage | 16.42 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.72 | |||||
Beneish M-Score | -2.67 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.5 | |||||
3-Year EBITDA Growth Rate | -15.1 | |||||
3-Year EPS without NRI Growth Rate | -49.6 | |||||
3-Year FCF Growth Rate | -7.9 | |||||
3-Year Book Growth Rate | 5.4 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 23.77 | |||||
9-Day RSI | 27.31 | |||||
14-Day RSI | 33.47 | |||||
3-1 Month Momentum % | 32.43 | |||||
6-1 Month Momentum % | 23.35 | |||||
12-1 Month Momentum % | 16.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.57 | |||||
Quick Ratio | 1.35 | |||||
Cash Ratio | 0.39 | |||||
Days Inventory | 223.51 | |||||
Days Sales Outstanding | 141.15 | |||||
Days Payable | 138.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.52 | |||||
Dividend Payout Ratio | 1.07 | |||||
Forward Dividend Yield % | 0.52 | |||||
5-Year Yield-on-Cost % | 0.53 | |||||
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | -2.23 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 71.43 | |||||
Operating Margin % | 12.38 | |||||
Net Margin % | 2.91 | |||||
EBITDA Margin % | 5.01 | |||||
FCF Margin % | 9.99 | |||||
OCF Margin % | 11.53 | |||||
ROE % | 3.26 | |||||
ROA % | 1.67 | |||||
ROIC % | 6.94 | |||||
3-Year ROIIC % | -4.75 | |||||
ROC (Joel Greenblatt) % | 7.94 | |||||
ROCE % | 4.45 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 95.08 | |||||
Forward PE Ratio | 12.28 | |||||
PE Ratio without NRI | 35.77 | |||||
Shiller PE Ratio | 24.8 | |||||
PEG Ratio | 3.34 | |||||
PS Ratio | 2.89 | |||||
PB Ratio | 3.13 | |||||
Price-to-Tangible-Book | 5.36 | |||||
Price-to-Free-Cash-Flow | 30.16 | |||||
Price-to-Operating-Cash-Flow | 25.77 | |||||
EV-to-EBIT | 59.42 | |||||
EV-to-EBITDA | 59.42 | |||||
EV-to-Revenue | 2.98 | |||||
EV-to-FCF | 29.8 | |||||
Price-to-GF-Value | 0.78 | |||||
Price-to-Projected-FCF | 1.79 | |||||
Price-to-Graham-Number | 2.92 | |||||
| Price-to-Net-Current-Asset-Value | 25.93 | |||||
Earnings Yield (Greenblatt) % | 1.68 | |||||
FCF Yield % | 3.59 | |||||
Forward Rate of Return (Yacktman) % | 1.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Guizhou Sanli Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,675.983 | ||
| EPS (TTM) (Â¥) | 0.12 | ||
| Beta | 1.2538 | ||
| 3-Year Sharpe Ratio | -0.15 | ||
| 3-Year Sortino Ratio | -0.24 | ||
| Volatility % | 55.84 | ||
| 14-Day RSI | 33.47 | ||
| 14-Day ATR (Â¥) | 0.838124 | ||
| 20-Day SMA (Â¥) | 13.311 | ||
| 12-1 Month Momentum % | 16.71 | ||
| 52-Week Range (Â¥) | 10.49 - 17.46 | ||
| Shares Outstanding (Mil) | 408.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Guizhou Sanli Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guizhou Sanli Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.060000 Cash Dividend | 2026-06-30 | 12.85 (-3.17%) | ||
| CNY 0.340000 Cash Dividend | 2025-06-26 | 11.98 (+0.08%) |
Show
Entries
Guizhou Sanli Pharmaceutical Co Ltd Frequently Asked Questions
What is Guizhou Sanli Pharmaceutical Co Ltd(SHSE:603439)'s stock price today?
The current price of SHSE:603439 is ¥11.41. The 52 week high of SHSE:603439 is ¥17.46 and 52 week low is ¥10.49.
When is next earnings date of Guizhou Sanli Pharmaceutical Co Ltd(SHSE:603439)?
The next earnings date of Guizhou Sanli Pharmaceutical Co Ltd(SHSE:603439) is .
Does Guizhou Sanli Pharmaceutical Co Ltd(SHSE:603439) pay dividends? If so, how much?
The Dividend Yield %  of Guizhou Sanli Pharmaceutical Co Ltd(SHSE:603439) is 0.52% (As of Today), Highest Dividend Payout Ratio of Guizhou Sanli Pharmaceutical Co Ltd(SHSE:603439) was 5.67. The lowest was 0.17. And the median was 0.53. The  Forward Dividend Yield % of Guizhou Sanli Pharmaceutical Co Ltd(SHSE:603439) is 0.52%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Guizhou Sanli Pharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers